Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS p.Gln61Lys (p.Q61K)
(
ENST00000369535.5 )
NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. NRAS mutations were in 4/40 tumors (three Q61K, one G12D).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2192
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/427
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Selumetinib,Dactolisib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22392911
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dactolisib | Sensitivity | true |
| Selumetinib | Sensitivity | true |